-
Product name:
Trifluoperazine
-
Generic name:
Trifluoperazine
-
Dosage form:
Oral tablets
-
Packaging:
Box of 5 blisters of 20 F.C. tablets
-
Drug Category:
Neurology and Psychiatry
Indications:
Low dosage: Trifluoperazine is indicated as an adjunct in the short-term management of anxiety states, depressive symptoms secondary to anxiety, and agitation. It is also indicated in the symptomatic treatment of nausea and vomiting.
High dosage: Treatment of symptoms and prevention of relapse in schizophrenia and in other psychosis, especially of the paranoid type, but not in depressive psychosis. It may also be used as an adjunct in the short-term management of severe psychomotor agitation and of dangerously impulsive behaviour in, for example, mental subnormality
Dosage and Administration:
Adults:
Low dosage: 2-4 mg a day, given in divided doses, according to the severity of the patient's condition. If necessary, dosage may be increased to 6 mg a day, but above this level extrapyramidal symptoms are more likely to occur in some patients.
High dosage: The recommended starting dose for physically fit adults is 5 mg twice a day; after a week this may be increased to 15 mg a day. If necessary, further increases of 5 mg may be made at three-day intervals, but not more often. When satisfactory control has been achieved, dosage should be reduced gradually until an effective maintenance level has been established.
As with all major tranquillizers clinical improvement may not be evident for several weeks after starting treatment, and there may also be delay before recurrence of symptoms after stopping treatment. Gradual withdrawal from high-dosage treatment is advisable.
Pediatric:
Low dosage: For children aged 6-12 years, up to a maximum of 4 mg a day given in divided doses.
High dosage: For children aged under 12 years, the initial oral dosage should not exceed 5mg a day, given in divided doses. Any subsequent increase should be made with caution, at intervals of not less than three days, and taking into account age, body weight and severity of symptoms.
Geriatric:
The starting dose for elderly or frail patients should be reduced by at least half.
Contraindication:
Known hypersensitivity to phenothiazines or to any of thew exipients.
Comatose or greatly depressed states due to CNS depressants.
Blood dyscrasias.
Bone marrow depression.
Pre-existing liver damage